Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : email@example.com
|Therapy Name||Idelalisib + Tirabrutinib|
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|Idelalisib||Zydelig||CAL-101|GS-1101||PIK3CD inhibitor 25||Zydelig (idelalisib) inhibits PI3K-delta, preventing the activation of the PI3K signaling pathway and inhibiting tumor cell proliferation, motility, and survival (PMID: 24450857). Zydelig (idelalisib) is FDA approved for follicular B-cell non-Hodgkin lymphoma, relapsed small lymphocytic lymphoma, and in combination with Rituxan (rituximab) for relapsed chronic lymphocytic leukemia (FDA.gov).|
|Tirabrutinib||ONO-GS-4059|ONO-WG-307|ONO-4059||BTK inhibitor 22||Tirabrutinib (ONO-4059) inhibits Bruton's Tyrosine Kinase (BTK), which leads to decreased B-cell proliferation and differentiation, and may have antitumor activity in B-cell malignancies (PMID: 23958373, PMID: 27776353, PMID: 32156743).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Unknown unknown||chronic lymphocytic leukemia||not applicable||Idelalisib + Tirabrutinib||Phase I||Actionable||In a Phase Ib trial, Tirabrutinib (ONO-4059) and Zydelig (idelalisib) combination treatment was well tolerated, resulted in a overall response rate of 93% (13/14) with complete response in 7% (1/14) of patients with chronic lymphocytic leukemia (PMID: 32156743; NCT02457598).||32156743|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status|